ImClone Systems' BEC-2 vaccine
Executive Summary
Elicits immune responses in three of five advanced malignant melanoma patients injected with the anti-idiotype to the GD3 antigen found on cancerous cells. The Memorial Sloan-Kettering study was reported May 20 to the American Association for Cancer Research in San Diego. Phase I trials have been expanded to include patients with earlier stage disease and to investigate an additive effect from BCG adjuvant (Detox). ImClone plans to file an IND this year for BEC-2 in treatment of small cell lung cancer.
You may also be interested in...
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Shire Hopes To Sow Future Deals With $50M Venture Fund
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth